Sedation - Pipeline Review, H2 2012

Publisher Name :
Date: 31-Oct-2012
No. of pages: 46
Inquire Before Buying

Sedation - Pipeline Review, H2 2012

Summary

Global Markets Direct's, 'Sedation - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Sedation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sedation. Sedation - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Sedation.
- A review of the Sedation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Sedation pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Sedation.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Sedation pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Sedation - Pipeline Review, H2 2012

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Sedation Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Sedation 7
Sedation Therapeutics under Development by Companies 9
Sedation Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Sedation Therapeutics - Products under Development by Companies 14
Sedation Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Sedation Therapeutics Development 16
AstraZeneca PLC 16
AcelRx Pharmaceuticals, Inc. 17
PAION AG 18
Mayne Pharma Limited 19
Sedation - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
CNS-7056 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
sufentanil + triazolam - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
zolpidem - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
propofol - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
dexmedetomidine hydrochloride - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Midazolam - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
PF0713 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
flumazenil - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Sedation Therapeutics - Drug Profile Updates 36
Sedation Therapeutics - Discontinued Products 38
Sedation Therapeutics - Dormant Products 39
Sedation - Product Development Milestones 40
Featured News & Press Releases 40
May 14, 2012: Ono Pharma Announces Phase II Study Results Of ONO-2745/CNS 7056 40
Oct 14, 2011: APP Pharmaceuticals Announces Increased Availability Of APP Diprivan And APP Propofol 1% 40
Jul 22, 2011: Orion Receives Positive CHMP Opinion For Dexdor 41
May 18, 2011: AcelRx Pharma Presents ARX-03 Clinical Study Results At 30th Annual Scientific Meeting Of American Pain Society 41
Nov 04, 2009: Paion Reports Positive Results Of Its Short Acting Anaesthetic/Sedative CNS 7056 In A Phase IIa Study In Upper GI Endoscopy 42
Apr 20, 2009: Paion Initiates Phase Ib Study Of The Anesthetic/Sedative CNS 7056 In Volunteers Undergoing Colonoscopy 43
Nov 19, 2008: Paion Announces Successful Completion Of Phase I Study With The Sedative/Anaesthetic CNS 7056 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46

List of Tables
Number of Products Under Development for Sedation, H2 2012 7
Products under Development for Sedation - Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
AstraZeneca PLC, H2 2012 16
AcelRx Pharmaceuticals, Inc., H2 2012 17
PAION AG, H2 2012 18
Mayne Pharma Limited, H2 2012 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Sedation Therapeutics - Drug Profile Updates 36
Sedation Therapeutics - Discontinued Products 38
Sedation Therapeutics - Dormant Products 39

List of Figures
Number of Products under Development for Sedation, H2 2012 7
Products under Development for Sedation - Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Discovery and Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24

  • Healthy Diet Demand In Developed Economies To Boost Nutraceuticals
    As customers scuffle to keep up with the frantic lifestyles, the necessity for healthy nutrition rises owing to dearth of time to spend on laborious exercises.  Customers are shifting their attention to swift and healthy food behaviours. Increase in intake of beverages and functional food has offered makers of nutraceuticals with money-spinning prospects to benefit [...]
  • World Economic Forum Unveils Top 10 Emerging Technologies of 2016
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies of 2016. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or [...]
  • Siemens Adds To the Growth of Wind Power Generation Market
    Siemens has been presenting ground-breaking strategies and pioneering solutions for energy generation for an intelligent power supply globally. With an expansive portfolio and wide-ranging proficiency in wind power generation, Siemens is likely to aid in increasing the share of wind power in the US energy mix. With New Mexico’s vicinity to significant wind energy areas, [...]
  • Global Public Safety LTE Ecosystem Overview
    In view of its flourishing ecosystem, spectrum flexibility and performance metrics, LTE has emerged as the leading candidate for public safety mobile broadband networks. Public safety organizations and establishments have already begun planning to advance their networks to LTE-based public safety solutions. LTE provisions a varied range of services, from high bandwidth data services to [...]
  • RnR Market Research: Biochips Market Insights
    Growing R&D investment and subcontracting of pharmaceutical companies would lead to growth in biochips market in Asia along with an increase in the application of biochips products is estimated to improve opportunity for the global biochip market. Conversely, the high cost involved in manufacturing of biochips can be seen as a challenge for the same. [...]
  • Cystic Fibrosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Sep-2016        Price: US 2000 Onwards        Pages: 100
    Summary DelveInsight's Report, "Cystic Fibrosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Cystic Fibrosis Report is to understand the market and pipeline status of the drugs around the Cystic Fibrosis to explore the generic development opportunities, licensing opportunitie......
  • Cysticercosis (Taeniasis)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Sep-2016        Price: US 2000 Onwards        Pages: 100
    Summary DelveInsight's Report, "Cysticercosis (Taeniasis)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Cysticercosis (Taeniasis) Report is to understand the market and pipeline status of the drugs around the Cysticercosis (Taeniasis) to explore the generic development opportu......
  • Hypercholesterolemia - Market Insights, Epidemiology and Market Forecast-2023
    Published: 01-Sep-2016        Price: US 4950 Onwards        Pages: 100
    Note*: This report requires 5-10 business days to complete. DelveInsight's Hypercholesterolemia - Market Insights, Epidemiology and Market Forecast-2023" Reports provides an overview of the disease and global market trends of the Crohn's disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Hypercholesterolemia fore......
  • Hyperparathyroidism - Market Insights, Epidemiology and Market Forecast-2023
    Published: 01-Sep-2016        Price: US 4950 Onwards        Pages: 100
    Note*: This report requires 5-10 business days to complete. DelveInsight's Hyperparathyroidism - Market Insights, Epidemiology and Market Forecast-2023" Reports provides an overview of the disease and global market trends of the Crohn's disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Hyperparathyroidism foreca......
  • Edema-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Sep-2016        Price: US 2000 Onwards        Pages: 100
    Summary DelveInsight's Report, "Edema-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Edema Report is to understand the market and pipeline status of the drugs around the Edema to explore the generic development opportunities, licensing opportunities and to gain competitive adva......
  • Hyperthyroidism - Market Insights, Epidemiology and Market Forecast-2023
    Published: 01-Sep-2016        Price: US 4950 Onwards        Pages: 100
    Note*: This report requires 5-10 business days to complete. DelveInsight's Hyperthyroidism - Market Insights, Epidemiology and Market Forecast-2023" Reports provides an overview of the disease and global market trends of the Crohn's disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Hyperthyroidism forecasted mar......
  • Empyema-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Sep-2016        Price: US 2000 Onwards        Pages: 100
    Summary DelveInsight's Report, "Empyema-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Empyema Report is to understand the market and pipeline status of the drugs around the Empyema to explore the generic development opportunities, licensing opportunities and to gain competitiv......
  • Enterobacteriaceae Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Sep-2016        Price: US 2000 Onwards        Pages: 100
    Summary DelveInsight's Report, "Enterobacteriaceae Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Enterobacteriaceae Infections Report is to understand the market and pipeline status of the drugs around the Enterobacteriaceae Infections to explore the generic develop......
  • Dyslipidemia  - Market Insights, Epidemiology and Market Forecast-2023
    Published: 01-Sep-2016        Price: US 4950 Onwards        Pages: 100
    Note*: This report requires 5-10 business days to complete. DelveInsight's Dyslipidemia - Market Insights, Epidemiology and Market Forecast-2023" Reports provides an overview of the disease and global market trends of the Crohn's disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Dyslipidemia forecasted market sh......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs